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The work presented here deals with the development of a quantitative tool for the determination
of the quaternary ammonium anticholinergic glycopyrrolate in human plasma samples. Mepenzolate
was used as an internal standard. The plasma samples were subjected to a suitable sample clean-up
consisting of a simple and relatively fast, two step liquid–liquid ion-pair extraction procedure. The
chromatography, using the same volatile ion-pair reagent heptaﬂuorobutyric acid (HFBA), takes only
10min. Relative standard deviation of retention times was never above 2.26% (n=36). The method
was fully validated based on the US FDA Bioanalytical Method Validation Guidance for Industry. As
such, a quantitative ESI-LC–MS(/MS) (TOF mass spectrometry) method was optimized for the absolute
quantiﬁcation of glycopyrrolate in human plasma in a concentration range from 0.101 to 101ng/mL
2 −4 −5 2 −2using a quadratic calibration function (R =0.9995), y=−2.21×10 (±3.93×10 )× x +5.85×10
(±5.27×10−3)× x+4.08×10−3 (±4.82×10−4). For the three QC concentrations (QC1 0.252, QC2 2.52, and
QC3 25.2ng/mL) and the LLOQ (0.101ng/mL), total precision was under 20% (18.0% (n=6) at the LLOQ) and
maximum accuracy was 112% (88.9% for the LLOQ, n=6). Absolute matrix effect (maximum 133%±9.59,
n=3), absolute recovery (better than 41.8%±2.22, n=3), relative (inter-subject) matrix effect (maximum
10.9%±1.45, n=4) and process efﬁciency (better than 45.2%±5.74, n=3) too were assessed at the 3 QC
t
G
t
i
i
r
k
t
p
dconcentrations.
. Introduction
Quaternary ammonium (QA) drugs are widely used as anti-
holinergic agents. Glycopyrrolate (GLY), as a synthetic QA
ompound, has been used for decades as a pre-operative antimus-
arinic. In addition, it diminishes the volume and free acidity
f gastric secretions and controls excessive pharyngeal, tracheal,
nd bronchial secretions [1–4]. In contrast to the tertiary amines
tropine sulfate and hyoscine hydrobromide, which are other
ell-known anticholinergic agents, the highly polar quaternary
mmoniumgroupofGLY limits its passage through theblood–brain
arrier. As a consequence, doses which cause these marked anti-
ialagogue actions have little effect on heart rate or pupil size.
ntraoperatively, GLY counteracts drug-induced or vagal traction
eﬂexeswith the associated arrhythmias and oral and gastric secre-
∗ Corresponding author. Tel.: +32 9 264 8131; fax: +32 9 264 8197.
E-mail address: Jan.VanBocxlaer@ugent.be (J.F. Van Bocxlaer).
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ions. Although many anesthesiologists still routinely make use of
LY because of the positive effects, its use has been cut back during
he last 20 years, due to the need for painful and anxiety-provoking
ntramuscular (IM) injection caused by short distribution and elim-
nation half-life [5]. Clifford et al. investigated other administration
outes, such as oral and intravenous (IV) routes. As expected by the
nown variable gastrointestinal absorption of GLY, oral administra-
ionwas found tobe ineffective. IVadministrationon theotherhand
roved to be superior to IM administration because of an additional
ecrease of gastric secretions, not seen by IM administration [1].
The scope of this study, as part of a larger clinical study, was to
evelop an analysis method for GLY, allowing a pharmacokinetic
valuation of patients treated with Robinul® after IV distribution
hrough an arterial catheter. Past PK studies in normal volunteers,
iven a single IV infusion of 0.4mg GLY, already indicated that the
rug undergoes a rapid distribution/elimination phase (t1/2 = 1.7h).
hepeakplasmaconcentrations occurwithin theminute after infu-
ion and no wide distribution to the tissues takes place [6]. As
or all anticholinergics, the duration of action varies, with possi-
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le antisialagogue effects for up to 7h. Each Robinul® injection vial
ontains 1mL of 0.4mg GLY, USP in water for injection with 9mg of
enzyl alcohol as preservative (Information for health profession-
ls, Robinul data sheet). For IM injection, the onset of reaction is
0–40min with peak plasma concentrations after approximately
0–45min and the duration of action ranging from 4 to 6h.
During the past decades, several studies investigated possi-
le quantitation approaches for GLY and other QA compounds.
ue to their cationic character, detection of the latter drugs is
till not straightforward. Coverage with immunoassays is lim-
ted. Traditionally, GLY was analyzed by using enzyme-linked
mmunosorbent assay (ELISA) [7,8]. However, cross-reactions are
ften noted. Methods using gas chromatography–mass spectrom-
try (GC–MS) on selected QA drugs have been developed but
ntact QA compounds cannot be analyzed with GC–MS [9–12].
ne approach is the hydrolysis of the isolated quaternary com-
ound to cyclopentylmandelic acid which is then amenable to
etection and conﬁrmation following derivatization and analysis
y GC–MS. A broad range of other chromatographic and spec-
rometric techniques have been reported for the analysis of QA
rugs [13–26]. An inherent disadvantage of most of these analyt-
cal methods is the lack of speciﬁcity, resulting in identiﬁcation
nd quantiﬁcation issues in complex matrices, e.g., plasma [13].
nly methods using mass spectrometry can unmistakably iden-
ify the detected analyte. Consequently, more speciﬁc methods like
apillary electrophoresis–mass spectrometry (CE–MS) have been
ptimized for the analysis of QA, however, only in (horse) urine [9].
or QA drugs, indeed, CE seems a better option considering the per-
anent ionic characteristicof theanalytemolecules.Unfortunately,
ouplingCE toMS is far fromroutineanddoes lack somerobustness.
Liquid chromatographymass spectrometry (LC–MS) at the other
and, usingelectrospray ionization (ESI), hasbecome themethodof
hoice in both quantitative and qualitative bioanalytical work due
o its speed, sensitivity, speciﬁcity and robustness [13]. In reversed
hase type of separations, ion-pair chromatography allows the
hromatographyof ionic analytes.Generally, ion-pair chromatogra-
hy is performed with high concentrations of non-volatile ion-pair
eagents, obviously incompatible with (ESI–)mass spectrometry.
ome of these issues can be overcome by phase-system switch-
ng using an ion-exchange trapping column (2D-LC) but, additional
quipment [17,27] is required and the complexity of the analytical
ethod is substantially enhanced. The use of volatile acids as ion-
airing agents was ﬁrst described by Castro et al. [12], allowing the
irect couplingof ion-pair chromatographyandmass spectrometry.
eptaﬂuorobutyric acid (HFBA), pentaﬂuoropropionic acid (PFPA)
nd triﬂuoroacetic acid (TFA) were selected as possible ion-pairing
gents. In their setup, HFBA yielded the most promising results.
sing the latter approach, Arifﬁn and Anderson [28] developed an
fﬁcient procedure for the simultaneousdeterminationofQAdrugs
nd herbicides in human whole blood using SPE extraction.
Solid phase extraction, mainly based upon cation-exchange,
s the most investigated extraction method for QA compounds
29]. Indeed, the cationic nature of the drugs does not lend itself
ell to liquid–liquid partition extraction methods [6,9,12–26].
iquid–liquid extractions can only be an alternative when ion pair-
ng is introduced. Ion pair extractionwas used for the analysis of QA
ompounds in urine by Murray et al. after adjusting the pH of the
rine to 10 and extracting the newly formed iodine-glycine drug
omplex into dichloromethane [27]. In this way, a simple ion-pair
iquid/liquid extraction was obtained with recoveries ranging from
6% to 90% [9]. A similar ion-pair liquid–liquid extraction utiliz-
ng heptane sulfonate is used by Rudy et al. for the quantitation
nd conﬁrmation of ipratropium in equine urine for screening pur-
oses. Of course, many of the ion-pairing reagents, e.g., heptane
ulfonate, do not lend themselves all too well to ESI-MS detection.
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In our approach, ion-pairing liquid/liquid extraction with
ichloromethane is adjusted to approximate the chemical environ-
ent of the ensuing LC–MS analysis by using the same ion-pairing
gent as used for the chromatographic separation step. In this way
FBA acts as ion-pairing agent for both the extraction and chro-
atographic separation step. This report is a detailed presentation
f the development, optimization and validation of this method for
oriented quantitative measurements.
. Experimental
.1. Chemicals
Pure reference standard of glycopyrrolate (USP quality, GLY)
as obtained from Boehringer Ingelheim Chemicals Inc. (Peters-
urg, USA). The internal standard, mepenzolate (Mp) was obtained
s mepenzolate bromide from Sigma–Aldrich (Bornem, Belgium).
C–MS grade methanol and acetonitrile were from Biosolve
Valkenswaard, The Netherlands). Ultrapure water was pro-
uced by a Synergy 185 system (Millipore Comp., Bedford,
A, USA). Heptaﬂuorobutyric acid, formic acid (p.a. 98%–100%),
ichloromethane and ammonium formate were purchased at
igma–Aldrich (Bornem, Belgium). Drug-free blank plasma (differ-
nt patient pools) was obtained at the local blood bank and kept
rozen until use.
.2. Analytical standards
Individual stock solutions of GLY (1.01×106 ng/mL) and Mp
1.01×106 ng/mL) were prepared by accurately weighing the
equired amounts in separate volumetric ﬂasks and dissolving in
ppropriate volumes of high purity water. These solutions were
ppropriately diluted in high purity water by serial dilution using
Hamilton diluter (Hamilton, Bonaduz, Switzerland) to obtain
he working standard solutions used to spike plasma calibrators
nd quality control samples (see Section 2.3). The following stan-
ard solutions were prepared: 101×102; 504×101; 101×101;
04ng/mL; 101; 75.7 and 50.4ng/mL. Separate weightings, dilu-
ions and volumetric material were used in the preparation of the
uality control sampleswhichwere also used in the accuracy inves-
igation method. All standards were kept at −20 ◦C and were used
or a maximum of 3 months.
.3. Calibrators and quality control samples
Calibrators in plasma were prepared by adding 20L of the
elevantworking standard solution to 1980L of blankplasma. Cal-
brators over a concentration range of 0.1–100ng/mL for GLY (101;
0.4; 10.1; 5.04; 1.01; 0.757; 0.504; 0.101ng/mL) were obtained.
uality control samples at three different levels (QC1 0.252, QC2
.52, and QC3 25.2ng/mL), different from the calibration concen-
rations, were separately prepared in larger pools.
Each calibration curve was acquired in triplicate allowing val-
dation of the calibration curves based upon the Food and Drug
dministration bioanalytical method validation guidance protocol
30]. In this context, precision, accuracy, limit of detection (LOD),
ower and upper limit of quantiﬁcation (LLOQ, resp. ULOQ) and
electivity were also determined. To that end, calibration curves
ere run on 6 different days. The concurrently analyzed (differ-
nt days, n=6), quality control samples were also used to calculate
otal precision and accuracy of the method. Using these samples,
ccuracy, as percentage error (100− [concentration(measured-
dded)/added]×100), was assessed. Two of the quality control
evels (QC1 0.252 and QC3 25.2ng/mL) were also used for a post-
xtraction stability study. The sampleswere repeatedly re-analyzed
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ver a 10h time interval (time frame of 60 samples) and the
esulting absolute peak areas were plotted against injection time.
valuation of the slope of this curve together with the percentage
esponse deviation compared to the time zero injection provides
tability data.
.4. Sample preparation and extraction
To1mLofplasmasample, aﬁxedamountofMp, as internal stan-
ard, was added (50L of a 1/2000 dilution of the stock solution;
5.2ng). Subsequently, 1mLof 0.2Mammonium formate (adjusted
o pH 3.0 with formic acid) and 4mL of dichloromethane were
dded. After 10min of rotation on a rotatory mixer, the tubes were
entrifuged for 20min at 2254× g (25 ◦C). 750L was removed
rom the upper water phase and transferred into new centrifuge
ubes. After addition of 1mL of 0.1M aqueous HFBA and 4mL of
ichloromethane, samples were rotated again on a rotatory mixer
or 10min. After centrifugation (20min, 2254× g, 25 ◦C), the upper
water) phase was removed as waste. The lower dichloromethane
ayer was evaporated to dryness under a nitrogen stream at 35 ◦C
TurboVap LV evaporator, Zymark). Following, dried samples were
edissolved in 200L of eluent A (15mMHFBA-20mMammonium
ormate buffer) before injection.
.5. Mobile phases
LC eluent A consisted of HFBA (15mM)-ammonium formate
uffer (20mM) adjusted to pH 3.30 with formic acid. Eluent B
as pure methanol. Both solvents (A) and (B) were ﬁltered over
0.45m membrane ﬁlter before use.
.6. Liquid chromatographyThe Atlantis dC18 (2.1mm I.D., length 50mm, particle size
m) used was purchased from Waters (Milford, MA, USA). The
hromatographic system consisted of an Alliance 2795 LC system
quipped with an analytical autosampler having a 100L injection
3
b
e
ig. 1. MS/MS spectrum (collision energy: 30eV) and chemical structure of Mp [A] and G
ode. m/z 318.4 (GLY) and m/z 340.3 were selected as precursor ion, m/z 116.2 (GLY) andgr. B 876 (2008) 24–30
oop installed. Isocratic elutionwas performedwith a ﬁxed compo-
ition of 30% eluent A and 70% eluent B at a ﬂow rate of 100L/min.
fter injection of 20L of sample, a total run cycle time of 10min
as used.
.7. Mass spectrometry
The HPLC system was interfaced with a QTOF1 mass spec-
rometer (Micromass-Waters, Manchester, UK), equipped with an
rthogonal electrospray source (Z-spray®) operated in the posi-
ive ion mode. The mass spectrometer was operated in the MS/MS
odeallowingmaximumsensitivity and speciﬁcity.Nitrogenacted
oth as nebulizer (60 L/h) and drying gas (580 L/h) and argon
erved as collision gas (4.5×10−3 mbar collision cell pressure). A
tandard 120m capillary was used in the electrospray ioniza-
ion (ESI) interface. The source was operated at 120 ◦C and the
esolvation temperature was 240 ◦C. Electrospray capillary and
one voltage were optimized to 3000 and 30V, respectively. Data
ere collected and processed using the MassLynx® and Quanlynx®
oftware (Micromass-Waters, Manchester, UK). Collision energy
as assessed to 30eV after infusion experiments with pure GLY
101ng/mL, m/z 318.4) and Mp standard (101ng/mL, m/z 340.3)
issolved in the same eluent composition of the isocratic chro-
atographic system, at 10L/min. Quantiﬁcation, after collision-
nduced dissociation of the respective precursor ions,m/z 318.4 and
/z340.3, occurs atm/z116.2 andm/z130.2 forGLYandMp, respec-
ively. In doing so, a sometimes so-called pseudo-MRM method is
btained. The MS/MS spectra and chemical structure of GLY and
p, as of their corresponding fragment ions are shown in Fig. 1.
. Results and discussion.1. Extraction procedure and its validation
Using the proposed procedure, GLY is extracted using a com-
ination of ion-pairing extraction with HFBA and liquid–liquid
xtraction. The same agent is also used as the mobile phase addi-
LY [B], acquired on a Micromass ESI-QTof 1 mass spectrometer in the positive ion
m/z 130.2 (Mp) were selected for quantiﬁcation.
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ive. In both cases, HFBA is added to counteract the highly polar
haracteristics of the quaternary ammonium group. During extrac-
ion, a broad range of proteins and lipids is removed in a ﬁrst step
nder acidic conditions using dichloromethane. A major part of the
pper water layer is separated from the dichloromethane layer by
ransferring 750L to a new centrifugation tube. Nearly half of
he water phase, composed of 1mL of plasma sample and 1mL
f 0.2M ammonium formate is as such thrown away as waste.
his proved inevitable, due to the formation of a white diffuse
ing between the two phases, mainly made up of plasma proteins.
ollowing, the HFBA solution is added and a second liquid–liquid
xtraction step with dichloromethane occurs. In contrast to the
rst step QA, like GLY and Mp, are now surrounded by the anionic
ounter-ions, becoming less polar as a whole and moving towards
he dichloromethane phase. The total water layer is then thrown
way and the resulting dichloromethane phase is nowahighly pure
xtract of cationic substances like QA.
Thus, by the use of 2 consecutive liquid–liquid extraction steps,
ne with and one without the addition of the counter-ion HFBA to
eutralize the permanent cationic nature of QA drugs, only minor
lasmaeffects, a critical issue in the validation of the assay accuracy
nd reliability, are expected. Indeed, in bioanalytical mass spec-
rometry, absolute matrix effects are almost inescapable. However,
uch more important is the demonstrable lack of relative matrix
ffects, i.e., variance between patient results brought about by the
nter-individual differences in the constitution of their plasma.
tandard validation efforts, based on pooled blank biological ﬂu-
ds do not reveal this possibility peculiar to (ESI)-LC–MS. In fact,
he assessment of matrix effect during development and valida-
ion of HPLC–MS(/MS) methods is also recommended by the U.S.
ood and Drug Administration (FDA) “to ensure that precision,
electivity, and sensitivity will not be compromised” [30]. To that
nd, matrix (plasma) effects were evaluated based on the sugges-
ions of Matuszewski et al. [31]. Thus, absolute matrix effect was
ssessed by spiking a quantity of target (GLY and Mp) into blank
lasma extract and comparing the area to the same quantity spiked
nto the solvent. The same solvent composition (30/70 (v/v) elu-
nt A/eluent B) as during the isocratic chromatographic separation
tep was used. This was done at all three of the QC concentration
evels (0.252; 2.52 and 25.2ng/mL) and in three-fold. Moreover,
he experiment was repeated for four plasma lots, originating from
our different individuals, allowing the evaluation of relativematrix
ffects too. Using the aforementioned method, the matrix effect
as 110%±20.1 (mean± SD; n=3) for QC1; 133%±9.59% for QC2
nd120%±6.84% forQC3. As can be seen, some ionization enhance-
ent (matrix effect >100%) is present.
The assessment of the relative matrix effect was based on
he variability of the peak area ratio GLY/Mp (n=3) spiked into
lank extracts of 4 different plasma lots [31]. In doing so, the rel-
tive matrix effect was 10.1%±3.34 (mean± SD; n=4) for QC1;
.47%±0.585 for QC2 and 10.9%±1.45 for QC3. This variability
eems to be comparable to or only slightly higher than theprecision
f determination of standards injected directly in the mobile phase
9.64%±0.776 (mean± SD; n=3); 5.13%±1.43 and 6.72%±0.491,
espectively). These data conﬁrm that the relative matrix effect has
ractically no effect on the quantiﬁcation of GLY.
The extraction efﬁciency was equally determined for the three
evels of quality control samples, based on the recommendations
y Matuszewski et al. as the concentration ratio of spiked plasma
xtract to blank plasma extract fortiﬁed with the same amount
f compound [31]. In doing so, absolute extraction recovery was
1.8%±2.22 (mean± SD; n=3), 45.3%±1.55 and 42.1%±4.27 for
C1, QC2 and QC3. The latter extraction recoveries seem to be low.
owever, taking into account that approximately half of the water
ayer is discarded during the ﬁrst liquid–liquid extraction step,
c
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otential extraction efﬁciency could be increased up to 80% by iso-
ating the maximum volume possible of water layer. This, however,
as not favored for ease of handling and in order to increase the
xtraction methods’ reproducibility.
Process efﬁciency, describing both plasma effect and extraction
fﬁciency combined, was calculated as the concentration ratio of
piked plasma extract to the same quantity spiked into pure eluent.
or the 3QC levels, process efﬁciencywas 45.2%±5.74 (mean± SD;
=3); 56.9%±6.41 and 49.2±2.00, respectively. Evidently, throw-
ng away nearly half of the water layer during the ﬁrst extraction
tep again affects these numbers.
.2. Chromatographic performance
The chromatographic separation step takes 10min under iso-
ratic conditions, i.e., 70% of eluent B. Different isocratic eluent
ompositions were evaluated. 30:70 of 15mM HFBA in 20mM
mmonium formate buffer (pH 3.30): methanol was ﬁnally pre-
erred as eluent composition based on retention time behavior.
minimal retention time (Tr) of 5min was aimed at, allowing
ufﬁcient chromatographic separation of potentially co-extracted
ubstances for one thing and a fast sample turnover time
or another. In doing so, Tr was 6.82±0.140min (mean± SD;
=36)min forGLY and6.02±0.152min (mean± SD;n=36)min for
he IS Mp. Fig. 2 shows typical mass chromatograms of GLY and Mp
or a blank serum, an LLOQ concentration level sample and a real
atient sample (vide infra).
.3. Calibration and method validation
For calibration purposes, the analyte to IS peak area ratio was
lotted against analyte concentration andweighed regression anal-
sis was applied to calculate the calibration curves. In doing so,
ata heteroscedasticity is counteracted and a higher weight is
llocated to the lower concentrations in the calibration curve, lead-
ng to an improved quantiﬁcation of the lower concentrations. A
eighing factor 1/X was chosen, based on the analysis of residu-
ls and accuracy of quality control samples. Quadratic calibration
urves (eight calibration points, one zero sample) gave the best ﬁt
ased on statistical regression analysis comparison (Statgraphics®,
anugistics, Inc., Rockville, MD), the analysis of residuals (i.e., low-
st absolute sum) and the acceptance criteria of the concomitant
uality control samples (QC1 0.252, QC2 2.52, and QC3 25.2ng/mL)
alculated according to the different ﬁts applied to a particular
alibration set. The advent of powerful automated quantiﬁcation
oftware tools, e.g., Quanlynx®,makes quadratic calibrationsnearly
s easy in use as linear ones, provided that one accepts the statis-
ically enforced requirement to use a somewhat larger number of
oints in the calibration exercise (8 calibrators are used instead of
minimal of 6 required for linear calibration curves). Nowadays
n LC–MS(/MS), especially with electrospray ionization (and in the
eld of TOF analyzers), linear calibration curves with a dynamic
ange exceeding 2 decades are hard to ﬁnd. We have often seen
hat electrospray ionization does not generate analyte ions a pri-
ri by a linear process, especially not over a larger concentration
rea. The latter is especially truewhen analyzing biological extracts
here extract impurity affects the ionization process. Thus, forcing
linear function through, in essence, curvilinear data rather intro-
uces accuracy errors [32]. Moreover, quadratic calibration curves
learly provide an extendedmeasurement interval, in our case from
.101 to 101ng/mL. Indeed, a linear calibration correlationwas only
bserved with the lower 6 calibrators included. At higher concen-
rations, the effectiveness of the electrospray ionization process
egins to deviate from an absolute linear process (see Fig. 3).
28 M.L. Storme et al. / J. Chromatogr. B 876 (2008) 24–30
Fig. 2. Typical mass chromatograms of Mp (upper trace m/z 340.3 to 130.2) and GLY (lower trace m/z 318.4 to 116.2) for a blank plasma sample [A]; a spiked plasma sample
at the LLOQ concentration level [B]; and for a real patient sample [C].
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Table 1
Accuracy, precision, absolute matrix effect, inter-subject variability, absolute recovery and process efﬁciency at the 3 QC concentration levels.
Concentration
(ng/mL)
Accuracy
(%; n=6)
Precision (total)
(%; n=6)
Precision
(within-day)
(%; n=4)
Absolute matrix effect
(mean%± SD; n=3)
Inter-subject variability
(mean%± SD; n=4)
Absolute recovery
(mean%± SD; n=3)
Process efﬁciency
(mean%± SD;
n=3)
L
Q .1
Q 59
Q 84
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4LOQ 0.101 88.9 18.0 – –
C1 0.252 112 13.9 7.22 111 ± 20
C2 2.52 105 9.32 8.43 133 ± 9.
C3 25.2 88.1 8.63 7.50 120 ± 6.
The mean values (±SD, n=6) of the quadratic equation coef-
cients were: y=−2.21×10−4 (±3.93×10−5)× x2 +5.85×10−2
±5.27×10−3)× x+4.08×10−3 (±4.82×10−4). The mean coefﬁ-
ient of determination (R2)was 0.9995 (n=6, RSD%0.0216). ANOVA
nalysis always revealed a statistically signiﬁcant calibration rela-
ionship at the99%conﬁdence level. The95%conﬁdence interval for
he intercept always included zero, statistically indicating that the
alibration curve passes through zero. The lower limit of quantiﬁ-
ation (LLOQ) was established at the level of the lowest calibrator,
.e., 0.101ng/mL, provided that an acceptable level of precision and
ccuracy is achieved. At this concentration, a signal to noise ratio
f 5.2, total precision (RSD%, n=6) of 18.0% and accuracy (n=6) of
8.9% was noted. These data are within the generally accepted vali-
ation criteria limits (precision <20% and accuracy between 80 and
20%). Accordingly, the ULOQ was established at the highest cal-
brator, being 101ng/mL. The, less informative, limit of detection
LOD) was deﬁned at a signal to noise ratio equal to 3 and approx-
mated from the lowest calibrator. In doing so, an LOD for GLY of
early 0.050ng/mL is achieved. Accuracy andprecision (within-day
r repeatability and total precision) of the LC–MS(/MS) method
ere further evaluated using the 3 different quality control lev-
ls. Within-day precision or repeatability remained below 9%, total
recision below 14.0%. Inaccuracy was at every QC concentration
evel below 15%. Again, these data are well within the generally
equired validation criteria limits, being maximum inaccuracy of
5% (20% at LLOQ) and precision below 15% (20% at LLOQ). All of the
bovementioned validation parameters are summarized in Table 1.
ost-extraction stability was evaluated at the QC1 and QC3 concen-
ration levels. A plot of the resulting absolute peak areas against
njection time revealeda small positive slope for theQC1 concentra-
ion and a small negative slope for theQC3 concentration. However,
he percentage deviation compared to the time zero injection was
ess than 13% (QC1), respectively 14% (QC3) indicating acceptable
tability.
Selectivity is an inherent aspect of LC–MS/MS procedures and
as conﬁrmed by the absence of signal in at least 6 blank plasma
xtracts of different patient origins.
ig. 3. Curvilinear calibration function of GLY, ranging from 0.101 to 101ng/mL.
hen the 2 highest calibrators (101 and 50.4ng/mL) are not included in the con-
entration response curve, the latter shifts to a more linear function.
d
p
v
r
e
l
u
t
a
e
r
f
c
i
q
a
A
(
G– – –
10.1 ± 3.34 41.8 ± 2.22 45.2 ± 5.74
5.47 ± 0.585 45.3 ± 5.55 56.9 ± 6.41
10.9 ± 1.45 42.1 ± 4.27 49.2 ± 2.00
.4. Study samples
The development and validation of the analytical method was
erformed as part of a clinical study for the pharmacokinetic
valuation of GLY concentrations after a single intravenous bolus
njection of Robinul®. Patient samples are sent to us by the Ghent
niversity Hospital (Department of Anesthesia). Informed con-
ent is obtained from all participants of the study, refusal to sign
n informed consent means exclusion from the study. In a pre-
iminary proof-of-concept trial, one female patient was selected
height: 159 cm; weight: 73kg). The patient had been treated pre-
peratively with tamoxifen for 7 days. Before the operation, one
olus injection of Robinul®, containing 0.4mg GLY, had been given
nd a blood sample was taken (T0). Following, a second and third
ample were taken after 5 and 10min (T5 and T10), respectively.
ll the samples were collected through an arterial line, plasma
as separated from the blood and stored at −80 ◦C. The study
amples were analyzed in batch in a sequence consisting of 2 sep-
rate calibration sample sets with the study samples in between
nd the required quality control samples interspersed within the
equence. In doing so, the measured concentration of GLY was
2.9 and 4.93ng/mL for T5 (see chromatogram in Fig. 2C) and
10, respectively. For T0, no GLY concentration was measurable
or detectable. The actual study will allow, among other clinical
tudy objectives, full evaluation of the pharmacokinetic character-
stics of GLY after a single bolus injection with Robinul® based on
n extended number of study patients. This study phase is in a
reliminary stage.
. Conclusion
A fully validated LC–MS(/MS) method was developed for the
etermination of GLY in human plasma. Method evaluation was
erformed in accordance to the widely accepted international
alidation standards as proposed by the US FDA. To obtain a
eliable LC–MS procedure, adequate sample clean-up proved nec-
ssary. This was achieved by a simple and relatively fast two step
iquid–liquid extraction procedure, a part with and without the
se of the counter-ion HFBA to neutralize the permanently posi-
ive charge state of QA drugs. In doing so, during validation relative
nd absolute matrix effects were found to be of insigniﬁcant inﬂu-
nce on the quantitation procedure. Other mandatory validation
esultswere also in concordancewith internationally accepted per-
ormance criteria. The same counter-ion was also used during the
hromatographic separation step using a standard C18 phase. The
socratic eluent LC–MS(/MS)method takesonly10minallowing the
uantiﬁcation of GLY over a concentration range of 3 decades with
fast sample turnover time.cknowledgements
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